Novartis to donate up to 130 million doses of hydroxychloroquine for COVID-19

Basel: Novartis has announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts and will evaluate the needs for additional clinical trials.

Medical Dialogues team had recently reported that hydroxychloroquine has been approved by the ICMR as a prophylactic measure in certain COVID cases.

Read Also: Breaking News: ICMR Permits Prophylactic Use Of Hydroxy—Chloroquine For Coronavirus; Check Out Indications, Doses

When supported for use in COVID-19 infected patients by regulatory authorities, Novartis intends to donate up to 130 million 200 mg doses by the end of May, including its current stock of 50 million 200 mg doses. The company is also exploring further scaling of capacity to increase supply and is committed to working with manufacturers around the world to meet global demand.

Novartis Sandoz division currently only holds registration for hydroxychloroquine in the U.S. and will pursue appropriate regulatory authorizations from the U.S. FDA and the European Medicines Agency. Novartis will work with stakeholders including the World Health Organization to determine the best distribution of the medicine to ensure broad access to patients most in need of this medicine globally. The company aims to ensure that patients currently depending on this medicine are not impacted by the donation.

The commitment announced today builds on the previously announced commitments of a USD 20 million Novartis COVID-19 Response Fund, drug discovery collaboration efforts, support of clinical trials for existing Novartis medicines, and the Sandoz commitment to maintaining stable prices on a basket of essential medicines that may help in the treatment of COVID-19.

Novartis intends to work closely with other manufacturers to scale up production of hydroxychloroquine as necessary to support global supply and encourages industry, governments, and international institutions to ensure adequate global supply of medications to treat COVID-19 patients.

Read also: Novartis Receives Japanese Approval For Zolgensma For Spinal Muscular Atrophy